<?xml version="1.0" encoding="UTF-8"?>
<p id="p0195">It is almost certain that novel and repurposed drugs will be needed in the fight against COVID-19 [
 <xref rid="bib119" ref-type="bibr">119</xref>,
 <xref rid="bib120" ref-type="bibr">120</xref>]. In this context, cocktail drugs with optimized relationships seem to be more realistic [
 <xref rid="bib121" ref-type="bibr">[121]</xref>, 
 <xref rid="bib122" ref-type="bibr">[122]</xref>, 
 <xref rid="bib123" ref-type="bibr">[123]</xref>]. The combination of anti-HIV Kaletra® (Lopinavir/Ritonavir) drug (3CLpro/PLpro inhibition) and α-interferon (immunomodulatory properties) has been used, but the therapeutic effect remains highly limited, and toxic side effects can occur [
 <xref rid="bib124" ref-type="bibr">124</xref>]. On the other hand, arbidol monotherapy has been shown superior to lopinavir/ritonavir in treating COVID-19 [
 <xref rid="bib125" ref-type="bibr">125</xref>] and contrariwise, combination therapy was associated with a significantly improved the chest CT scans in 7-day [
 <xref rid="bib126" ref-type="bibr">126</xref>].
</p>
